Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | BTK | Q06187 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | PRKACA | P17612 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | LCK | P06239 | 2/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.37 |
| ▸ | LYN | P07948 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | BLK | P51451 | 2/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5550935 | 0.76 | BTK (0.43) | GAABTKKDRPDPK1JAK2 | |
| SCHEMBL1848211 | 0.76 | GAA (0.32) | GAAGRIA1CACNG8 | |
| SCHEMBL31190661 | 0.76 | GAA (0.32) | GAAGRIA1CACNG8 | |
| SCHEMBL7703073 | 0.76 | ADORA2A (0.34) | GAABTKGRIA1CACNG8 | |
| SCHEMBL186280 | 0.72 | GAA (1.00) | GAAKDRPDPK1JAK2JAK1 | |
| SCHEMBL6927615 | 0.72 | BTK (0.50) | GAABTKKDRPDPK1PRKACA | |
| SCHEMBL1703256 | 0.69 | BTK (0.67) | BTKKDRPDPK1JAK2TYK2 | |
| SCHEMBL16681057 | 0.69 | GAA (0.58) | GAAKDRPDPK1JAK2JAK1 | |
| SCHEMBL12325103 | 0.68 | GAA (0.61) | GAAKDRPDPK1JAK2JAK1 | |
| SCHEMBL31261144 | 0.66 | GAA (0.49) | GAAKDRPDPK1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124177-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12508245-B2 | Co-therapies including a metastasis inhibitor | NOVITA PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250333411-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY (US) | 2025-10-30 | — | — | US | disclosed |
| US-12168658-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240124449-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2017-06-08 | — | — | US | disclosed |
| US-9573946-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573946-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573946-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| EP-3107902-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") (US) | 2016-12-28 | — | — | EP | disclosed |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2015-10-22 | — | — | US | disclosed |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2015-10-22 | — | — | US | disclosed |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2015-10-22 | — | — | US | disclosed |
| WO-2015127125-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY (US) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015127125-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124449-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | GAA 630/4885BTK 4560/4885KDR 4832/4885 |
| US-12508245-B2 | Co-therapies including a metastasis inhibitor | PDCD1, CD274, PDCD4 | GAA 4225/4885BTK 349/4885KDR 1516/4885 |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | GAA 630/4885BTK 4560/4885KDR 4832/4885 |
| US-20250333411-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | GAA 630/4885BTK 4560/4885KDR 4832/4885 |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | GAA 630/4885BTK 4560/4885KDR 4832/4885 |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | MIF, CXCL10, CCL2 | GAA 3948/4885BTK 715/4885KDR 589/4885 |
| US-12168658-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | GAA 630/4885BTK 4560/4885KDR 4832/4885 |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | GAA 630/4885BTK 4560/4885KDR 4832/4885 |
| US-20260124177-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | CCR10, CCR4, OGFR | GAA 4826/4885BTK 1717/4885KDR 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.